U.S. Veterinary Orthopedic Medicine Market Size, Share & Trends Analysis Report By Product (Biologics, Viscosupplements, Pharmaceuticals), By Animal Type, By Application, By Route Of Administration, By End-use, And Segment Forecasts, 2024 - 2030

Market Size & Trends

The U.S. veterinary orthopedic medicine market size was estimated at USD 503.41 million in 2023 and is expected to grow at a compound annual growth rate (CAGR) of 7.2% from 2024 to 2030. Factors such as an increasing pet population, advancements in veterinary medicine, growing adoption of pet insurance, and rising prevalence of orthopedic diseases among animals, primarily drives market growth. For instance, according to an article published by Frontiers, in 2022, OA is a prevalent orthopedic condition in dogs, affecting 2.5% clinically. However, when assessed post-mortem, its prevalence significantly increases to 20%, emphasizing widespread impact within a canine population.

Increasing incidence of osteoarthritis in dogs is contributing to market growth. In 2022, National Center for Biotechnology Information data revealed that veterinarians diagnosed osteoarthritis in 38% (188 out of 500) dogs. This rise in diagnoses is attributed to factors such as obesity, which is linked to orthopedic issues in both dogs and cats. Consequently, there is a growing demand for diverse medications and treatments to address orthopedic problems in these animals.

Advancements in treatment of orthopedic diseases through developing new products and approvals from the FDA for various veterinary orthopedic medicines are driving market growth. For instance, in October 2023, the FDA sanctioned Librela (bedinvetmab injection) as first monoclonal antibody designed to alleviate osteoarthritis-related pain in dogs. For instance, in April 2022, American Regent Animal Health, a division of American Regent, Inc., obtained FDA approval to prolong the shelf life of Adequan Canine and Adequan I.M. Also, expiration period for both products was extended from 24 months to 36 months from the manufacturing date. These advancements, stemming from increased research and development endeavors, are expected to fuel market growth.

Market Concentration & Characteristics

The U.S. veterinary orthopedic medicine market is characterized by a medium degree of innovation, with new technologies and methods being developed and introduced regularly.

Several market players, such as VetStem, Inc., Zoetis, and Contura Vet are involved in merger and acquisition activities. Through M&A activity, these companies can expand their geographic reach and enter new territories.

The FDA's rigorous regulation of regenerative medicine impacts the market by establishing a critical framework for market entry. Stringent approval processes influence how companies bring their products to market, ensuring a focus on safety and efficacy.

A wide range of product substitutes are available for canine and equine orthopedic disease management. Substitutes include alternative methods of treating orthopedic problems, such as surgeries. Threat due to external substitutes is high as these substitutes offer numerous advantages in orthopedic treatment.

Product Insights

The pharmaceuticals segment held the largest revenue share of 46.7% in 2023. According to the NCBI article published in November 2022, the “pharmaceuticals” segment is integral, focusing on using Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) in equine veterinary medicine. These drugs, phenylbutazone & flunixin, are routinely employed for their analgesic and anti-inflammatory properties to manage a spectrum of conditions in horses, ranging from abdominal to orthopedic pain.

The viscosupplements segment is anticipated to witness fastest market growth over the forecast period. absence of effective disease-modifying drugs poses a challenge in halting or reversing OA in horses, and existing treatment regimens primarily focus on mitigating clinical signs linked to OA. Unfortunately, joint diseases often prompt early retirement or euthanasia in horses. The treatment goals for joint diseases involve reducing pain and lameness while curbing progression of joint degeneration. Substances like polyacrylamide hydrogel and HA, known as viscosupplements, offer potential solutions. These substances enhance joint function by providing lubrication, reducing friction, and supporting joint structure. Viscosupplements have emerged as valuable components in the comprehensive strategy to manage and improve orthopedic health of equine athletes by decreasing pain, alleviating lameness, and minimizing joint degeneration.

Animal Type Insights

The dogs segment held the largest revenue share in 2023 and is estimated to register the fastest CAGR over the forecast period. Increasing participation of dogs in agility competitions serves as a growth driver for the U.S. veterinary orthopedic medicine market, owing to the need for specialized care to address specific orthopedic challenges arising from such activities.

A NCBI survey result published in November 2021 examining orthopedic conditions in dogs participating in agility competitions offered significant insights. According to dog owners, 41.7% reported injuries in their agility-engaged dogs, highlighting potential orthopedic challenges associated with such activities. As more dogs engage in these activities, the demand for veterinary orthopedic services increases.

Application Insights

The osteoarthritis segment dominated the market in 2023. Canine osteoarthritis (OA) is prevalent, clinically affecting 2.5% of dogs, but post-mortem assessments reveal a 20% prevalence, underscoring its widespread impact. Veterinary practices face challenges in managing OA, which is acknowledged as a hindering condition. Physiotherapy, exercise, and pharmaceutical interventions, highlighted in a 2023 NCBI article, are crucial for enhancing dogs' mobility and quality of life, with a new "Physiotherapy Pyramid" offering a systematic and practical guide for effective treatment in the market.

The others segment is anticipated to grow fastest during the forecast period. Other segment addresses soft tissue injuries in dogs, such as problems with muscles and ligaments. Dealing with these issues is complex and requires a specialized approach beyond the usual bone-related concerns. Hence, veterinarians need specific strategies to undertake the unique challenges posed by muscle and ligament problems in dogs, showcasing awareness of the diverse health issues in canine companions.

Route of Administration Insights

Injectables dominated the market in 2023. Presence of leading players manufacturing and supplying injectable medications for veterinary orthopedics is contributing to segment growth. Injectable segment is sub-segmented into intramuscular and intra-articular, among others. Injectable route of administration refers to administering medication or other substances directly into the body through various routes of administration. Some examples of various injectables include Adequan i.m., Betavet, Polyglycan, and Dexium.

Others are anticipated to witness the fastest market growth over the forecast period. Other segment includes topical route of medication. Various topical medications are applied on the dermal or skin of the joints and areas where the animal feels pain, and medication can relieve minor pain. An example of topical medications is SURPASS, which is used for horses.

End-use Insights

Veterinary hospitals & clinics dominated the market in 2023. Hospitals serve as critical hubs for diagnosing, treating, and rehabilitating orthopedic conditions in animals. Examples of orthopedic services in veterinary hospitals include surgical interventions for fractures, joint disorders, and ligament injuries. Utilization of advanced technologies and techniques in these hospital settings demonstrates continuous evolution of veterinary orthopedic medicine. The growth of this market segment is influenced by increasing awareness among pet owners regarding the availability of advanced orthopedic treatments for their animals.

Others are anticipated to witness fastest market growth over the forecast period. The other segment encompasses academic and research institutes, which are pivotal in advancing field. These institutions contribute significantly to the market through cutting-edge research, innovation, and educational initiatives. Academic institutes undertake in-depth studies to advance orthopedic treatments and methodologies, fostering a deeper understanding of animal musculoskeletal issues. Research institutes focus on developing innovative technologies that shape the future of veterinary orthopedic medicine. Their influence extends beyond clinical services, contributing to the sector's growth.

Key Companies & Market Share Insights

• Zoetis Services LLC commercializes products across species, such as dogs, cats, & horses (companion animals) and cattle, swine, poultry, fish, and sheep (livestock), with major products, such as vaccines, parasiticides, dermatology, anti-infective, and other pharmaceuticals products, medicated feed additives & animal health diagnostics

• Boehringer Ingelheim International GmbH has a portfolio of more than 200 products for dogs, cats, horses, pigs, cattle, and poultry. In addition, this company provides services for pets, equine, and swine in the field of veterinary public health

• Arthrex is a prominent global medical device company renowned for its commitment to advancing orthopedics through innovative product development and medical education

• PetVivo, Inc. is a wholly-owned subsidiary, including Gel-Del Technologies, Inc. and CosmetaLife Corporation, all operating under PetVivo Holdings, Inc.

• VetStem specializes in autologous stem cell processing from a patient's own fat tissue. They provide veterinarians with effective solutions for treating joint, tendon, and ligament issues, making regenerative medicine a practical therapeutic option in veterinary care

Recent Developments:

• In October 2023, Ardent Animal Health engaged in a licensing arrangement with Athersys, Inc. Through this partnership, Athersys' commitment to improving veterinary care is emphasized.

• In May 2023, FDA approved Zoetis’s Librela (bedinvetmab injection), making it first monoclonal antibody for treating osteoarthritis pain in dogs.

• In March 2023, VetStem, Inc. acquired three new GMP manufacturing and R&D facilities in the San Diego Biopharma corridor to accommodate its rapid growth.

U.S. Veterinary Orthopedic Medicine Market Report Scope

U.S. Veterinary Orthopedic Medicine Market Report Segmentation

This report forecasts revenue growth at a country level and provides an analysis of the industry trends in each of the sub-segments from 2018 to 2030. For this study, Grand View Research has segmented the U.S. veterinary orthopedic medicine market report based on product, animal type, application, route of administration, and end-use:

• Product Outlook (Revenue, USD Million, 2018 - 2030)

  • Biologics

    • Stem Cells

    • Platelet-Rich Plasma (PRP)

    • Other Biologics

  • Viscosupplements

  • Pharmaceuticals

    • Steroids

    • NSAIDS

    • Others

• Animal Type Outlook (Revenue, USD Million, 2018 - 2030)

  • Dogs

    • Small Breeds

    • Medium Breeds

    • Large Breeds

  • Horses

• Application Outlook (Revenue, USD Million; 2018 - 2030)

  • Osteoarthritis

  • Degenerative Joint Disease

  • Others

• Route Of Administration Outlook (Revenue, USD Million, 2018 - 2030)

  • Injectable

    • Intra-Muscular

    • Intra-Articular

    • Others

  • Oral

  • Others

• End-use Outlook (Revenue, USD Million, 2018 - 2030)

  • Veterinary Hospitals & Clinics

  • At-home

  • Others